Erratum: Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2, 3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer (Journal of Medicinal Chemistry (2012) 55 (8091-8109) DOI: 10.1021/jm300967g);Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazin-6-yl)-1 H -pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer

Journal of Medicinal Chemistry

Volumn 55, Issue 18, 2012, Pages 8091-8109

  Cui, J Jean ^a   McTigue, Michele ^a   Nambu, Mitchell ^a   Tran Dubé, Michelle ^a   Pairish, Mason ^a   Shen, Hong ^a   Jia, Lei ^a   Cheng, Hengmiao ^a   Hoffman, Jacqui ^a   Le, Phuong ^a   Jalaie, Mehran ^a   Goetz, Gilles H ^a   Ryan, Kevin ^a   Grodsky, Neil ^a   Deng, Ya Li ^a   Parker, Max ^a   Timofeevski, Sergei ^a   Murray, Brion W ^a   Yamazaki, Shinji ^a   Aguirre, Shirley ^a   Li, Qiuhua ^a   Zou, Helen ^a   Christensen, James ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2(4(1 (QUINOLIN 6 YLMETHYL) 1H [1,2,3] TRIAZOLO [4,5 B] PYRAZIN 6 YL) 1H PYRAZOL 1 YL) ETHANOL; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; PROTEIN KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG IDENTIFICATION; DRUG SAFETY; DRUG STRUCTURE; ENZYME BINDING; EPITHELIAL MESENCHYMAL TRANSITION; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROTEIN STRUCTURE;

EID: 84866872286     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3014647     Document Type: Erratum

References (52)

1. Comoglio, P. M.; Tamagnone, L.; Boccaccio, C. Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth Exp. Cell Res. 1999, 253, 88-99
2. Comoglio, P. M.; Trusolino, L. Invasive growth: from development to metastasis J. Clin. Invest. 2002, 109, 857-862
3. Maulik, G.; Shrikhande, A.; Kijima, T.; Ma, P. C.; Morrison, P. T.; Salgia, R. Role of the hepatocyte growth factor receptor, c-MET, in oncogenesis and potential for therapeutic inhibition Cytokine Growth Factor Rev. 2002, 13, 41-59
4. Ma, P. C.; Maulik, G.; Christensen, J.; Salgia, R. c-MET: structure, functions and potential for therapeutic inhibition Cancer Metastasis Rev. 2003, 22, 309-325
5. Christensen, J.; Burrows, J.; Salgia, R. c-MET as a target in human cancer and characterization of inhibitors for therapeutic intervention Cancer Lett. (Amsterdam, Neth.) 2005, 225, 1-26
6. Benvenuti, S.; Comoglio, P. M. The met receptor tyrosine kinase in invasion and metastasis J. Cell. Physiol. 2007, 213, 316-325
7. Knudsen, B. S.; Vande Woude, G. Showering c-MET-dependent cancers with drugs Curr. Opin. Genet. Dev. 2008, 18, 87-96
8. Cheng, H.-L.; Trink, B.; Tzai, T.-S.; Liu, H.-S.; Chan, S.-H.; Ho, C.-L.; Sidransky, D.; Chow, N.-H. Overexpression of c-MET as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation J. Clin. Oncol. 2002, 20, 1544-1550
9. Lengyel, E.; Prechtel, D.; Resau, J. H.; Gauger, K.; Welk, A.; Lindemann, K.; Alanti, G.; Richter, T.; Knudsen, B.; Vande Woude, G. F.; Harneck, N. c-MET overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu Int. J. Cancer 2005, 113, 678-682
10. Lo Muzio, L.; Farina, A.; Rubini, C.; Coccia, E.; Capogreco, M.; Colella, G.; Leonardi, R.; Campisi, G.; Carinci, F. Effect of c-MET expression on survival in head and neck squamous cell carcinoma Tumor Biol. 2006, 27, 116-121
11. Sawada, K.; Radjabi, A. E.; Shinomiya, N.; Kistner, E.; Kenny, H.; Becker, A. R.; Turkyilmaz, M. A.; Salgia, R.; Yamada, S. D.; Vande Woude, G. F.; Tretiakova, M. S.; Lengyel, E. c-MET overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion Cancer Res. 2007, 67, 1670-1679
12. Drebber, U.; Baldus, S. E.; Nolden, B.; Grass, G.; Bollschweiler, E.; Dienes, H. P.; Hölscher, A. H.; Mönig, S. P. Overexpression of c-MET as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation Oncol. Rep. 2008, 19, 1477-1483
13. Matsumoto, K.; Nakamura, T. Mechanism and significance of bifunctional NK4 in cancer treatment Biochem. Biophys. Res. Commun. 2005, 333, 316-327
14. Otsuka, T.; Jakubczak, J.; Vieira, W.; Bottaro, D. P.; Breckenridge, D.; Larochelle, W. J.; Merlino, G. Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis Mol. Cell. Biol. 2000, 20, 2055-2065
15. Matsumoto, K; Nakamura, T.; Sakai, K.; Nakamura, T. Hepatocyte growth factor and Met in tumor biology and therapeutic applications with NK4 Proteomics 2008, 8, 3360-3370
16. Burgess, T.; Coxon, A.; Meyer, S.; Sun, J.; Rex, K.; Tsuruda, T.; Chen, Q.; Ho, S.-Y.; Li, L.; Kaufman, S.; McDorman, K.; Cattley, R. C.; Sun, J.; Elliott, G.; Zhang, K.; Feng, X.; Jia, X.-C.; Green, L.; Radinsky, R.; Kendall, R. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors Cancer Res. 2006, 66, 1721-1729
17. Jin, H.; Yang, R.; Zheng, Z.; Romero, M.; Ross, J.; Bou-Reslan, H.; Carano, R. A.D.; Kasman, I.; Mai, E.; Young, J.; Zha, J.; Zhang, Z.; Ross, S.; Schwall, R.; Colbern, G.; Merchant, M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival Cancer Res. 2008, 68, 4360-4368
18. van der Horst, E. H.; Chinn, L.; Wang, M.; Velilla, T.; Tran, H.; Madrona, Y.; Lam, A.; Ji, M.; Hoey, T. C.; Sato, A. K. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo Neoplasia 2009, 11, 355-364
19. Liu, X.; Newton, R. C.; Scherle, P. A. Development of c-MET pathway inhibitors Expert Opin. Invest. Drugs 2011, 20, 1225-1241
20. Tuma, R. S. Novel antibody, rilotumumab (AMG 102) shows activity in metastatic colorectal cancer patients Oncology Times 2011, 33, 22-23
21. Catenacci, D. V. T.; Henderson, L.; Xiao, S.-Y.; Patel, P.; Yauch, R. L.; Hegde, P.; Zha, J.; Pandita, A.; Peterson, A.; Salgia, R. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence Cancer Discovery 2011, 1, 573-579
22. Surati, M.; Patel, P.; Peterson, A.; Salgia, R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies Expert Opin. Biol. Ther. 2011, 11, 1655-1662
23. Spigel, D. R.; Ervin, T. J.; Ramlau, R.; Daniel, D. B.; Goldschmidt, J. H.; Blumenschein, G. R.; Krzakowski, M. J.; Robinet, G.; Clement-Duchene, C.; Barlesi, F.; Govindan, R.; Patel, T.; Orlov, S. V.; Wertheim, M. S.; Zha, J.; Pandita, A.; Yu, W.; Yauch, R. L.; Patel, P. H.; Peterson, A. C. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3-7, 2011; Abstr. 7505.
24. Mroczkowski, B.; McTigue, M. A..; Sarup, J.; Murray, B. W.; Hickey, M.; Parge, H.; Zhu., J. Catalytic domains of the human hepatocyte growth factor receptor kinase and material and methods for identification thereof. USP 277968, EP1243596A1, 2001.
25. Schiering, N.; Knapp, S.; Marconi, M.; Flocco, M. M.; Cui, J.; Perego, R.; Rusconi, L.; Cristiani, C. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET and its complex with the microbial alkaloid K-252a Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12654-12659
26. Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K.-A.; Mock, L.; Tracy Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F. M.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A. H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 2009, 69, 8009-8016
27. Srinivasan, R.; Choueiri, T. K.; Vaishampayan, U.; Rosenberg, J. E.; Stein, M. N.; Logan, T.; Bukowski, R. M.; Mueller, T.; Keer, H. N.; Linehan, W. M. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). Presented at ASCO 2008 Annual Meeting, Chicago, IL, May 30-June 3, 2008; Abstr. 5103.
28. Jhawer, M. P.; Kindler, H. L.; Wainberg, Z. A.; Hecht, J. R.; Kerr, R. O.; Ford, J. M.; Henderson, C.; Mueller, T.; Keer, H. N.; Shah, M. A. Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study. Presented at ASCO 2008 Annual Meeting, Chicago, IL, May 30-June 3, 2008; Abstr. 4572.
29. Katz, J. D.; Jewell, J. P.; Guerin, D. J.; Lim, J.; Dinsmore, C. J.; Deshmukh, S. V.; Pan, B.-S.; Marshall, C. G.; Lu, W.; Altman, M. D.; Dahlberg, W. K.; Davis, L.; Falcone, D.; Gabarda, A. E.; Hang, G.; Hatch, H.; Holmes, R.; Kunii, K.; Lumb, K. J.; Lutterbach, B.; Mathvink, R.; Nazef, N.; Patel, S. B.; Qu, X.; Reilly, J. F.; Rickert, K. W.; Rosenstein, C.; Soisson, S. M.; Spencer, K. B.; Szewczak, A. A.; Walker, D.; Wang, W.; Young, J.; Zeng, Q. Discovery of a 5 H -benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer J. Med. Chem. 2011, 54, 4092-4108
30. Rickert, K. W.; Patel, S. B.; Allison, T. J.; Byrne, N. J.; Darke, P. L.; Ford, R. E.; Guerin, D. J.; Hall, D. L.; Kornienko, M.; Lu, J.; Munshi, S. K.; Reid, J. C.; Shipman, J. M.; Stanton, E. F.; Wilson, K. J.; Young, J. R.; Soisson, S. M.; Lumb, K. J. Structural basis for selective small molecule kinase inhibition of activated c-Met J. Biol. Chem. 2011, 286, 11218-11225
31. Cui, J. J.; Tran-Dubé, M.; Shen, H.; Nambu, M.; Kung, P. P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54, 6342-6363
32. Kwak, E. L.; Bang, Y.-J.; Camidge, R.; Shaw, A. T.; Solomon, B; Maki, R. G.; Ou, S.-H. I.; Dezube, B. J.; Jänne, P. A.; Costa, D. B.; Varella-Garcia, M.; Kim, W.-H.; Lynch, T. J.; Fidias, P.; Stubbs, H.; Engelman, J. A.; Sequist, L. V.; Tan, W.; Gandhi, L.; Mino-Kenudson, M.; Wei, G. C.; Shreeve, S. M.; Ratain, M. J.; Settleman, J.; Christensen, J. G.; Haber, D. A.; Wilner, K.; Salgia, R.; Shapiro, G. I.; Clark, J. W.; Iafrate, A. J. Anaplastic lymphoma kinase inhibition in non-small-cell-lung cancer N. Engl. J. Med. 2010, 363, 1693-1703
33. Ou, S.-H. I.; Kwak, E. L.; Siwak-Tapp, C.; Dy, J.; Bergethon, K.; Clark, J. W.; Camidge, D. R.; Solomon, B. J.; Maki, R. G.; Bang, Y.-J.; Kim, D.-W.; Christensen, J.; Tan, W.; Wilner, K. D.; Salgia, R.; Iafrate, A. J. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification J. Thorac. Oncol. 2011, 6, 942-946
34. Chi, A. S.; Kwak, E. L.; Clark, J. W.; Wang, D. L.; Louis, D. N.; Iafrate, A. J.; Batchelor, T. Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3-7, 2011; Abstr. 2072.
35. Lennerz, J. K.; Kwak, E. L.; Michael, M.; Fox, S. B.; Ackerman, A.; Bergethon, K.; Lauwers, G. Y.; Christensen, J. G.; Wilner, K. D.; Haber, D. A.; Salgia, R.; Bang, Y.; Clark, J. W.; Solomon, B. J.; Iafrate, A., J. Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3-7, 2011; Abstr. 4130.
36. Munshi, N.; Jeay, S.; Li, Y.; Chen, C. R.; France, D. S.; Ashwell, M. A.; Hill, J.; Moussa, M. M.; Leggett, D. S.; Li, C. J. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity Mol. Cancer Ther. 2010, 9, 1544-1553
37. Sequist, L. V.; von Pawel, J.; Garmey, E. G.; Akerley, W. L.; Brugger, W.; Ferrari, D.; Chen, Y.; Costa, D. B.; Gerber, D. E.; Orlov, S.; Ramlau, R.; Arthur, S.; Gorbachevsky, I.; Schwartz, B.; Schiller, J. H. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer J. Clin. Oncol. 2011, 29, 3307-3315
38. Timofeevski, S. L.; McTigue, M. A.; Ryan, K.; Cui, J.; Zou, H. Y.; Zhu, J. X.; Chau, F.; Alton, G.; Karlicek, S.; Christensen, J. G.; Murray, B. W. Enzymatic characterization of c-MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors Biochemistry 2009, 48, 5339-5349
39. Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J.-Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, S.; Luu, T. L.; Tang, F.; Wei, J. Cho, Tang. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3 Z)-ylidenemethyl]-2,4- dimethyl-1 H -pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase J. Med. Chem. 2003, 46, 1116-1119
40. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and x-ray crystallographic analysis J. Med. Chem. 2001, 44, 4339-4358
41. Christensen, J. G.; Schreck, R.; Burrows, J.; Kuruganti, P.; Chan, E.; Le, P.; Chen, J.; Wang, X.; Ruslim, L.; Blake, R.; Lipson, K. E.; Ramphal, J.; Do, S.; Cui, J. J.; Cherrington, J. M.; Mendel, D. B. A selective small molecule inhibitor of c-MET kinase inhibits c-MET-dependent phenotypes in vitro and exhibits cytoreductive antimutor activity in vivo Cancer Res. 2003, 63, 7345-7355
42. Koenig, M.; Cui, J.; Wei, C. C.; Do, S. H.; Zhang, F.-J.; Vojkovsky, T.; Ramphal, J.; Yang, G.; Mattson, M.; Nelson, C.; Tang, P. C. Indolinone hydrazides as c-met inhibitors. PCT Int. Appl. WO2005005378, 2005.
43. Vojkovsky, T.; Koenig, M.; Zhang, F.-J.; Cui, J. Tetracyclic compounds as c-Met inhibitors. PCT Int. Appl. WO2005004808, 2005.
44. Zhang, F.-J.; Vojkovsky, T.; Huang, P.; Liang, C.; Do, S. H.; Koenig, M.; Cui, J. Preparation of triazolotriazines as c-Met modulators for treating cancer. PCT Int. Appl. WO2005010005, 2005.
45. Cui, J.; Botrous, I. Arylmethyl triazolo and imidazopyrazines as c-MET inhibitors. PCT Int. Appl. WO2005004607, 2005.
46. Zou, H. Y.; Li, Q.; Lee, J. H.; Arango, M. E.; Burgess, K.; Qiu, M.; Engstrom, L.; Yamazaki, S.; Parker, M.; Timofeevski, S.; Cui, J. J.; McTigue, M.; Los, M. G.; Bender, S.; Smeal, T.; Christensen, J. G. Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor Mol. Cancer Ther. 2012, 11, 1036-1047
47. Yamazaki, S.; Skaptason, J.; Romero, D.; Vekich, S.; Jones, H. M.; Tan, W.; Wilner, K.; Koudriakova, T. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically-based pharmacokinetic modeling versus traditional one-compartment model Drug Metab. Dispos. 2011, 39, 383-393
48. Trust, R. I.; Albright, J. D.; Lovell, F. M.; N. A. Perkinson, N. A. 6- and 7-aryl-1,2,4-triazolo[4,3- b ]-1,2,4-triazines. Synthesis and characterization J. Heterocycl. Chem. 1979, 16, 1393-1403
49. Marusyk, A.; Vanessa Almendro, V.; Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer 2012, 12, 323-334
50. Szerlipa, N. J.; Pedrazab, A.; Chakravartyb, D.; Azimc, M.; McGuirec, J.; Fangd, Y.; Ozawae, T.; Hollande, E. C.; Hused, J. T.; Jhanward, S.; Levershac, M. A.; Mikkelseni, T.; Brennan, C. W. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response Proc. Natl. Acad. Sci. U.S.A 2012, 109, 3041-3046
51. Gerlinger, M.; Rowan, A. J.; Horswell, S.; Larkin, J.; David Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; Varela, I.; Phillimore, B.; Begum, S.; McDonald, N. Q.; Butler, A.; Jones, D.; Raine, K.; Latimer, C.; Santos, C. R.; Nohadani, M.; Eklund, A. C.; Spencer-Dene, B.; Clark, G; Pickering, L.; Stamp, G.; Gore, M.; Szallasi, Z.; Downward, J.; Futreal, P. A.; Swanton, C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 2012, 366, 883-892
52. Zou, H. Y.; Li, Q.; Lee, J. H.; Arango, M. E.; McDonnell, S. R.; Yamazaki, S.; Tatiana B. Koudriakova, T. B.; Alton, G.; Cui, J. J.; Kung, P.-P.; Nambu, M. D.; Los, G.; Bender, B. L.; Mroczkowski, B.; Christensen, J. G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res. 2007, 67, 4408-4417